Marvel Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 08-12-2024
- Paid Up Capital ₹ 5.00 M
as on 08-12-2024
- Company Age 38 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.27 Cr
as on 08-12-2024
- Revenue -22.14%
(FY 2022)
- Profit -58.61%
(FY 2022)
- Ebitda -44.44%
(FY 2022)
- Net Worth 8.48%
(FY 2022)
- Total Assets 3.30%
(FY 2022)
About Marvel Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.27 Cr.
Nikhil Shah and Abhishek Shah serve as directors at the Company.
- CIN/LLPIN
U24230MH1986PTC039868
- Company No.
039868
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 1986
- Date of AGM
11 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Marvel Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nikhil Shah  | Managing Director | 21-Sep-1987 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abhishek Shah | Director | 19-Dec-2002 | Current |
Financial Performance and Corporate Structure Insights of Marvel Drugs.
Marvel Drugs Pvt Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 22.14% decrease. The company also saw a substantial fall in profitability, with a 58.61% decrease in profit. The company's net worth moved up by a moderate rise of 8.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Marvel Drugs?
In 2021, Marvel Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 19 Apr 2022 | ₹2.90 M | Open |
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 24 Jan 2017 | ₹0.20 M | Open |
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 09 Mar 2016 | ₹0.20 M | Open |
How Many Employees Work at Marvel Drugs?
Marvel Drugs has a workforce of 34 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Marvel Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Marvel Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
